ClinicalTrials.gg
RecruitingNCT07553273Updated Nov 3, 2026

Vibratory Anesthesia on Pain Following Corticosteroid Injections

An interventional study of Digivibe Device in Bilateral Arthritis of Wrist, Tendinopathy and Arthropathy, sponsored by The University of Texas Medical Branch, Galveston. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by The University of Texas Medical Branch, Galveston · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2026, registered Apr 2026).
  • Started Jan 2026; still recruiting 9 months later.
Updated Nov 3, 2026Study documents postedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This research study aims to evaluate injectional pain at the site of needle insertion for corticosteroid injections (CSI) of the upper extremity depending on different modes of anesthetics. Each individual's perception of pain upon receiving a CSI with two out of three modes of anesthesia (control/no anesthesia, vibrational anesthesia, vapo-coolant anesthesia) will be utilized to compare these variables and determine the method that is associated with the least pain.

Read the detailed description

As part of standard medical care, participants receive corticosteroid injections to the bilateral upper extremities. Following written informed consent, participants undergo the study procedures described below. Each participant receives a total of two injections, with one injection administered in each arm during a single study visit.

The type of anesthesia used for each injection is determined by random assignment using a computer-generated randomization sequence within the REDCap system. Participants are assigned to one of the following anesthesia combinations:

No anesthesia and vapocoolant spray topical anesthetic applied prior to injection No anesthesia and vibration anesthesia using the DigiVibe device throughout the duration of the injection Vapocoolant spray topical anesthetic applied prior to injection combined with vibration anesthesia using the DigiVibe device throughout the duration of the injection

For participants assigned to a DigiVibe group, the device is applied directly to the skin. The device contains a circular component that contacts the skin surface and provides vibratory stimulation. The injection is administered within the circular area while vibration is applied.

Upon completion of each injection, participants complete a numeric pain rating scale to assess perceived pain and comfort associated with the anesthesia method used.

Both corticosteroid injections are administered as part of routine clinical care. The use of topical anesthetic and/or vibratory anesthesia is performed solely for research purposes. The total duration of the study visit is approximately 20 minutes.

02

Conditions studied

  • Bilateral Arthritis of Wrist
  • Tendinopathy
  • Arthropathy
  • Compression Neuropathy
  • Bilateral Arthritis of Hands

Keywords

  • Pain in Hand
  • Pain in Elbow
  • Pain in Wrist
03

In context

Tendinopathy

397 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.

This study's planned enrollment of 165 is above the median of 48 across 332 interventional studies indexed under Tendinopathy.

Browse Tendinopathy studies →

Lead sponsor

The University of Texas Medical Branch, Galveston is the lead sponsor of 257 studies on the registry; 38 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient of the Principal Investigator who has clinically diagnosed bilateral arthritis, tendinopathy, arthropathy, or compression neuropathy of the hand, wrist, or elbow where treatment with injection is indicated.
  • Participants who voluntarily consent to participate in the study and sign consent forms.
  • Participants who complete all numeric pain rating scales
  • Patients aged ≥ 18 years old

Exclusion criteria

Exclusion Criteria:

  • Participants who opt out of the study or withdraw consent
  • Participants who are determined to be without capacity to consent to study participation or injection procedure by principal investigator
  • Participants with inability to complete numeric pain rating scales
  • Participants with known allergies to triamcinolone acetonide, lidocaine, or bupivicaine
  • Participants without clinically diagnosed bilateral arthritis, tendinopathy, arthropathy, or compression neuropathy of the hand, wrist, or elbow.
  • Participants where treatment with injection is not indicated bilaterally.
  • Patients ≤ 18 years old
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (estimated)

Study arms

  • No intervention
    Limb A: No Anesthesia and Limb B: Vapocoolant Spray Anesthesia

    No anesthesia and vapocoolant spray topical anesthetic prior to injection. Participant will complete post-injection numeric pain rating scale assessing pain of injection.

  • Experimental
    Limb A: No Anesthesia and Limb B:Vibration Anesthesia (DigiVibe)

    Limb A: no anesthesia and Limb B:vibration anesthesia using the Digivibe device throughout the duration of the injection. Vibratory anesthesia will be administered throughout the duration of the injection. The circular part of the device will be applied directly to the surface of the skin. At the center of the circle is where the injection will be given, and the vibration will be turned on throughout the duration of the injection. After typical disposal of injection syringe, participant will complete post-injection numeric pain rating scale assessing pain of injection.

    Device: Digivibe Device

  • Experimental
    Limb A: Vapocoolant Spray Anesthesia Limb B: Vibration Anesthesia (DigiVibe)

    Limb A: vapocoolant spray topical anesthetic prior to injection and Limb B: vibration anesthesia using the Digivibe device throughout the duration of the injection Vapocoolant spray anesthesia will be applied until the skin blanches, which is the standard clinical use. Corticosteroid injection will be given. After typical disposal of injection syringe, participant will complete post-injection numeric rating score.

    Device: Digivibe Device

Interventions

  • DeviceDigivibe Device

    The Digivibe device uses pulsed vibrations to activate larger nerve fibers to interfere with pain signals. It has a circular shape to allow for injections in an area surrounded by pain-blocking vibrations.

06

What researchers measure

Primary outcomes

  1. Pain Intensity During Corticosteroid Injection With Topical Anesthesia in the Hand

    Pain intensity will be assessed using a validated pain scale (e.g., 0-10 Numeric Rating Scale \[NRS\]) at the time of corticosteroid injection in the hand, wrist, or elbow. (0 being none 10 being worst possible pain)

    Time frame: At time of injection (immediately following corticosteroid injection procedure)

  2. Pain Intensity During Corticosteroid Injection With Topical Anesthesia in the Elbow

    Pain intensity will be assessed using a validated pain scale (e.g., 0-10 Numeric Rating Scale \[NRS\]) at the time of corticosteroid injection in the hand, wrist, or elbow. (0 being none 10 being worst possible pain)

    Time frame: At time of injection (immediately following corticosteroid injection procedure)

  3. Pain Intensity During Corticosteroid Injection With Topical Anesthesia in the Wrist

    Pain intensity will be assessed using a validated pain scale (e.g., 0-10 Numeric Rating Scale \[NRS\]) at the time of corticosteroid injection in hand, wrist, or elbow. (0 being none 10 being worst possible pain)

    Time frame: At time of injection (immediately following corticosteroid injection procedure)

Secondary outcomes

  1. Change in Pain Intensity From Baseline to Injection in the Arm

    Change in participant-reported pain intensity will be calculated as the difference between baseline pain (prior to injection) and pain during injection using a 0-10 Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst possible pain. Scores will be compared across intervention groups (vibratory anesthesia, vapocoolant spray anesthesia, and no anesthesia).

    Time frame: Baseline (pre-injection) to time of injection

  2. Change in Pain Intensity From Baseline to Injection in the Elbow

    Change in participant-reported pain intensity will be calculated as the difference between baseline pain (prior to injection) and pain during injection using a 0-10 Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst possible pain. Scores will be compared across intervention groups (vibratory anesthesia, vapocoolant spray anesthesia, and no anesthesia).

    Time frame: Baseline (pre-injection) to time of injection

  3. Change in Pain Intensity From Baseline to Injection in the Wrist

    Change in participant-reported pain intensity will be calculated as the difference between baseline pain (prior to injection) and pain during injection using a 0-10 Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst possible pain. Scores will be compared across intervention groups (vibratory anesthesia, vapocoolant spray anesthesia, and no anesthesia).

    Time frame: Baseline (pre-injection) to time of injection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Apr 2027, 15 months after the start.

Of 174 non-industry interventional studies with no phase under Tendinopathy, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 15 months is below that.

Counting every sponsor, half of 183 studies reached it within 20 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
Apr 27, 2026
StartActual
Jan 14, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Show all 1 update

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07553273
Responsible party
Sponsor
First posted
Apr 27, 2026
Start date
Jan 14, 2026
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

John Faillace, MD,FAAOS
Contact
jofailla@utmb.edu
409-772-1011
Alice Lee
Contact
alklee@utmb.edu
409-772-1011

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion